MCL1 and prostate carcinoma: Although our results suggest that the posttranslational control of Mcl-1 stability becomes more important during prostate cancer progression, more experiments in prostate cancer tissues or primary prostate cancer cells are still required to substantiate the role of Mcl-1 and USP9x as factors responsible for a poor response to radiotherapy during prostate cancer progression.